Xyzal: Advanced Relief for Year-Round Allergy Symptoms
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.15 | $43.00 (0%) | 🛒 Add to cart |
| 30 | $1.89 | $64.50 $56.76 (12%) | 🛒 Add to cart |
| 60 | $1.63 | $129.00 $98.04 (24%) | 🛒 Add to cart |
| 90 | $1.38 | $193.50 $123.84 (36%) | 🛒 Add to cart |
| 120 | $1.12 | $258.00 $134.16 (48%) | 🛒 Add to cart |
| 180 | $0.86 | $387.00 $154.80 (60%) | 🛒 Add to cart |
| 270 | $0.69 | $580.50 $185.76 (68%) | 🛒 Add to cart |
| 360 | $0.60
Best per pill | $774.00 $216.72 (72%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.67 | $40.42 (0%) | 🛒 Add to cart |
| 90 | $0.54 | $60.63 $49.02 (19%) | 🛒 Add to cart |
| 120 | $0.46 | $80.84 $55.04 (32%) | 🛒 Add to cart |
| 180 | $0.41 | $121.26 $73.10 (40%) | 🛒 Add to cart |
| 270 | $0.34 | $181.89 $92.88 (49%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $242.52 $108.36 (55%) | 🛒 Add to cart |
Synonyms | |||
Xyzal (levocetirizine dihydrochloride) is a next-generation antihistamine specifically formulated to provide powerful, 24-hour relief from both indoor and outdoor allergy symptoms. As the active enantiomer of cetirizine, it offers enhanced binding affinity to H1 receptors with a optimized pharmacokinetic profile. This prescription-strength medication targets the root cause of allergic responses while minimizing sedative effects, making it suitable for daily use in managing chronic allergic conditions. Clinical studies demonstrate superior efficacy in reducing nasal and ocular symptoms compared to first-generation antihistamines.
Features
- Contains 5 mg levocetirizine dihydrochloride per tablet
- Once-daily dosing provides 24-hour symptom control
- Rapid onset of action within 1 hour of administration
- Minimal metabolism required (primarily renal excretion)
- Low potential for drug interactions due to limited hepatic processing
- Available in prescription and over-the-counter formulations
- Non-sedating at recommended doses for most patients
- Demonstrated efficacy in perennial and seasonal allergic rhinitis
- Proven effectiveness in chronic idiopathic urticaria management
- Child-appropriate formulations available (oral solution)
Benefits
- Provides comprehensive relief from sneezing, rhinorrhea, nasal congestion, and ocular symptoms
- Enables improved sleep quality by reducing nighttime allergy disruptions
- Supports daytime productivity through minimal CNS depression
- Allows for consistent symptom control with convenient once-daily dosing
- Reduces inflammatory markers associated with allergic responses
- Suitable for long-term management of chronic allergic conditions
Common use
Xyzal is primarily indicated for the relief of symptoms associated with perennial allergic rhinitis and seasonal allergic rhinitis in adults and children six years of age and older. These symptoms include rhinorrhea, sneezing, nasal congestion, pruritus of the nose/palate/throat, and ocular manifestations such as lacrimation, redness, and itching. Additionally, Xyzal is approved for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in patients aged six months and older, providing relief from wheals and pruritus associated with this condition. Off-label uses may include adjunctive therapy in allergic asthma and atopic dermatitis management, though these applications require physician supervision.
Dosage and direction
For adults and children 12 years and older: 5 mg (one tablet) once daily in the evening. For children 6 to 11 years: 2.5 mg (one-half tablet) once daily in the evening. The recommended dose for children 6 months to 5 years is 1.25 mg (2.5 mL oral solution) once daily in the evening. Administration should occur at approximately the same time each day, with or without food. Tablets should be swallowed whole with water and not crushed or chewed. For patients with renal impairment (creatinine clearance 30-49 mL/min): 2.5 mg once daily; (creatinine clearance 10-29 mL/min): 2.5 mg every other day; (creatinine clearance <10 mL/min): contraindicated. Hepatic impairment alone does not require dosage adjustment, but combined renal and hepatic impairment necessitates reduced dosing.
Precautions
Patients should exercise caution when engaging in activities requiring mental alertness, such as operating machinery or driving, until their response to the medication is established. Although Xyzal demonstrates lower sedative potential than first-generation antihistamines, individual responses may vary. Alcohol and other CNS depressants may potentiate any sedative effects. Use with caution in patients with predisposing factors for urinary retention (e.g., prostatic hyperplasia, spinal cord lesions), as anticholinergic effects may occur. Regular monitoring of renal function is recommended for patients with compromised renal systems. Elderly patients may be more susceptible to adverse reactions and should initiate therapy at lower doses. Pregnancy Category B: use only if clearly needed. Not recommended during breastfeeding due to secretion in human milk.
Contraindications
Xyzal is contraindicated in patients with known hypersensitivity to levocetirizine, cetirizine, or any component of the formulation. Patients with end-stage renal disease (creatinine clearance <10 mL/min) or undergoing dialysis should not use this medication. Concomitant use with other centrally-acting antihistamines is not recommended. The oral solution formulation contains sodium methylparaben and sodium propylparaben and is contraindicated in patients with known parabens allergy.
Possible side effects
Most common adverse reactions (≥2%) include somnolence (6-14%), nasopharyngitis (3-6%), fatigue (3-5%), dry mouth (2-5%), and pharyngitis (2-3%). Less frequent side effects may include headache, dizziness, nausea, and abdominal pain. Pediatric patients may experience pyrexia, cough, and epistaxis. Rare but serious adverse effects include severe hypersensitivity reactions (anaphylaxis, angioedema), seizures, tachycardia, and hepatitis. Psychiatric effects including agitation, aggression, and hallucinations have been reported rarely. Any persistent or severe side effects should prompt discontinuation and medical consultation.
Drug interaction
Although Xyzal has low interaction potential, caution is advised with CNS depressants including alcohol, barbiturates, benzodiazepines, and opioid analgesics. Theophylline may decrease levocetirizine clearance by approximately 16%. No clinically significant interactions have been observed with warfarin, azithromycin, ketoconazole, or erythromycin. P-glycoprotein inhibitors might increase levocetirizine absorption, though clinical significance remains uncertain. Always inform healthcare providers of all concomitant medications, including over-the-counter products and herbal supplements.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. Consistent daily dosing maintains optimal therapeutic levels, so establishing a routine (e.g., evening administration) improves adherence and efficacy.
Overdose
Symptoms of overdose may include drowsiness, agitation, restlessness, and tachycardia. In children, initial agitation may be followed by sedation. General supportive measures are recommended, including gastric lavage if ingestion occurred within 2 hours. Hemodialysis removes approximately 76% of circulating levocetirizine over 4 hours and should be considered in severe cases. There is no specific antidote. Monitor vital signs and provide symptomatic treatment. Contact poison control center (1-800-222-1222) or emergency services immediately for guidance.
Storage
Store at room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep in original container with tight closure to protect from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Oral solution should not be frozen. Properly discard any unused medication after treatment completion.
Disclaimer
This information does not replace professional medical advice. Consult a healthcare provider for diagnosis and appropriate treatment decisions. Individual responses to medication may vary. Only a qualified healthcare professional can determine the appropriate therapy based on medical history, current condition, and other factors. Report any adverse effects to your physician and the FDA MedWatch program.
Reviews
Clinical trials demonstrate 70-80% of patients experience significant symptom improvement within the first treatment week. Patient satisfaction surveys indicate high ratings for effectiveness in reducing nasal congestion and improving sleep quality. Approximately 15% of users report mild drowsiness during initial treatment, though most develop tolerance within several days. Healthcare providers consistently rate Xyzal as a first-line option for allergic rhinitis management due to its favorable efficacy-to-safety profile. Long-term users appreciate the consistent 24-hour coverage and minimal side effect burden compared to older antihistamines.